Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: Results of the FEATURE trial - Gottlieb, A B; Blauvelt, A; Prinz, J C (J Drugs Dermatol, 2016)
et al.